ArticleInfection2026
Transmitted HIV-1 drug resistance and subtype distribution among treatment-naïve individuals at a tertiary referral centre in the Aegean Region of Türkiye: an eight-year cohort study.
Article in Infection, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTransmitted drug resistance (TDR) threatens the effectiveness of first-line antiretroviral therapy, yet contemporary regional data from the Aegean region of Türkiye remain limited. This study evaluated TDR prevalence, mutational profiles, and HIV-1 subtype distribution among treatment-naïve individuals.
methodsWe conducted a single-center retrospective cohort study at a tertiary referral center in İzmir, Türkiye, including adults with confirmed HIV-1 infection who were antiretroviral-naïve at baseline between January 2017 and December 2024. Genotypic resistance testing was performed before treatment initiation using Sanger sequencing. Resistance mutations were interpreted with Stanford HIVdb v10.1, and TDR was defined as a penalty score of ≥ 10 for at least one drug.
resultsA total of 163 individuals were included; the mean age was 38.16 ± 12.48 years, 91.4% were male, and subtype B was the most common clade (50.3%). Overall, 29 individuals (17.8%) had at least one resistance-associated mutation. NNRTI resistance predominated (15.3%), followed by NRTI (1.8%) and PI (0.6%); no INSTI mutations were detected. HIV-1 subtype F remained independently associated with antiretroviral resistance in multivariable logistic regression (OR 31.4, 95% CI 6.10-335.1; p < 0.001). E138A was the most common NNRTI substitution (7.4%). S68G was the most frequent accessory mutation, identified in 41.7% of patients.
conclusionTransmitted drug resistance remains clinically relevant in treatment-naïve individuals in the Aegean region of Türkiye and is driven predominantly by NNRTI-associated mutations. The absence of baseline INSTI resistance supports the preserved activity of contemporary INSTI-based first-line regimens, while the observed association between subtype F and resistance warrants further molecular surveillance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.